Obesity Linked To Worse Outcomes In Early Breast Cancer Treatment
Obesity is associated with worse outcomes overall in early-stage breast cancer, researchers reported at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011. Obesity was linked to shorter time to recurrence (TTR), disease-free survival (DFS) and overall survival (OS). The exception was treatment with endocrine therapy (mainly tamoxifen), in which obesity was associated with a protective effect. "The findings add to the body of evidence indicating that obesity, in general, increases a patient's chance for having a worse prognosis, " said lead researcher Sao Jiralerspong, M.
In Mouse Model, Combination Therapy Shows Potent Tumor Growth Inhibition
Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, being held Nov. 12-16, 2011. "These preclinical findings suggest that combining REGN910 (SAR307746) and aflibercept in the clinic could be an attractive approach for future clinical research, " said Alshad S.
Anemia In Dialysis Patients - Peginesatide Gets Green Light From FDA Advisory Panel
An FDA Advisory Committee has voted in favour of approving peginesatide for use with dialysis patients who developed anemia caused by CKD ( chronic kidney disease ). The Oncologic Drugs Advisory Committee (ODAC) voted 15 in favor, 1 against, with 1 abstention. Peginesatide is an ESA (synthetic erythropoiesis-stimulating agent). The Panel (Advisory Committee) wrote that peginesatide was shown to have a favorable benefit/risk profile. President and CEO of Affymax, John Orwin, said: "We're encouraged by the panel's positive view of the benefit/risk profile of peginesatide in the dialysis setting.